Combined targeting of mevalonate pathway/PRC2 shows anticancer effect in BAP1-mutated mesothelioma
Feb. 2, 2023
Mesotheliomas are highly aggressive cancers with short overall survival, which can be extended only by a few months with currently approved therapies. Around 60%-70% of malignant mesotheliomas present mutated or deleted BAP1 tumor suppressor. BAP1 is a catalytic subunit of the polycomb repressive deubiquitinating (PR-DUB) complex, and its loss results in epigenetic alterations.